The fatigue, the achy joints, the brain fog that won't lift — so many women in perimenopause and beyond chalk these up to 'just menopause' and are told the same. What nobody mentioned was that iron could be quietly piling up in the background, masquerading as every other midlife symptom. Getting a ferritin test added to routine bloodwork shouldn't require a fight, but for a lot of women, it does.
Learn more about Rose →Menstruation eliminates roughly 0.5–1 mg of iron per day on average across a cycle, which acts as a continuous regulatory mechanism keeping stored iron (ferritin) from climbing too high. When periods cease, this loss disappears entirely and the body has no equivalent compensatory pathway to replace it. The gut does not automatically downregulate iron absorption to compensate, meaning intake continues but the exit route has closed.
Estrogen upregulates hepcidin, the master hormone that controls how much iron the gut absorbs and how much is released from storage cells. As estrogen falls during perimenopause and menopause, hepcidin signaling becomes less robust, which can allow intestinal iron uptake to increase beyond what the body actually needs. This hormonal shift is poorly understood by most clinicians and is almost never discussed in the context of menopause iron risk.
Hereditary hemochromatosis, one of the most common genetic disorders in people of Northern European descent, causes the gut to absorb iron at abnormally high rates regardless of the body's actual needs. In women who carry the HFE gene mutations responsible, menstrual blood loss masks the condition entirely during reproductive years — ferritin stays manageable because iron is constantly being shed. Once menstruation stops, the underlying genetic overload mechanism is fully unmasked, and ferritin can climb steeply within a few years if not identified and treated.
Excess iron preferentially deposits in the liver, where it drives oxidative stress, promotes fibrosis, and can accelerate the progression of non-alcoholic fatty liver disease (NAFLD) — a condition already more common in postmenopausal women due to metabolic shifts. Liver iron overload often produces no pain, no jaundice, and no acute warning signs until structural damage is advanced. Elevated liver enzymes on routine bloodwork are sometimes the only early clue, yet they are rarely connected to iron status in a menopause context.
Free iron catalyzes the Fenton reaction, generating hydroxyl radicals that oxidize LDL cholesterol and damage arterial endothelium — a mechanism that independently raises cardiovascular risk. Postmenopausal women already experience a sharp rise in cardiovascular disease risk as estrogen's protective effects on vessels decline; elevated iron adds a second, synergistic pathway for arterial damage that standard cardiovascular risk assessments do not account for. Several large observational studies have found associations between elevated ferritin and increased risk of coronary artery disease in postmenopausal women specifically.
Iron accumulation in the pancreas impairs beta-cell function and insulin secretion, while liver iron overload worsens hepatic insulin resistance — both mechanisms that push blood sugar dysregulation higher. Conversely, insulin resistance itself impairs hepcidin signaling, further loosening the brake on iron absorption and perpetuating the cycle. Postmenopausal women navigating metabolic changes are already at increased risk for type 2 diabetes, and elevated iron is an underappreciated accelerant that almost never appears on the differential in a standard workup.
Iron deposits in synovial tissue and cartilage trigger inflammation and progressive joint damage — a condition called iron arthropathy — most commonly affecting the knuckles of the second and third fingers but also the hips, knees, and ankles. Because joint pain is extremely common in perimenopause due to estrogen withdrawal, iron arthropathy is routinely attributed to hormonal changes and never investigated further. Women can spend years cycling through anti-inflammatories and physical therapy for joint pain that is fundamentally a storage disease problem.
Standard menopause bloodwork typically includes FSH, estradiol, thyroid function, and sometimes a lipid panel — ferritin is not a routine inclusion despite being the most clinically useful marker of iron storage status. Many women are told their iron is fine based only on a serum iron or hemoglobin result, neither of which reflects iron stores accurately; serum iron fluctuates daily and hemoglobin stays normal until iron overload is already severe. Requesting a full iron panel — serum iron, TIBC, transferrin saturation, and ferritin — requires a woman to specifically ask, and many clinicians will push back that it is unnecessary.
Paradoxically, both iron deficiency and iron overload cause fatigue — but the mechanisms differ entirely, and treating overload with iron supplements (as sometimes happens when fatigue is assumed to be deficiency) can cause serious harm. Iron overload fatigue arises from cellular energy dysfunction, mitochondrial oxidative stress, and early organ infiltration rather than from inadequate oxygen-carrying capacity. Because fatigue is so universal in perimenopause and menopause, iron overload as a contributing cause is essentially never considered unless a woman already has a known diagnosis — meaning the accumulation continues unchecked while the symptom is managed symptomatically.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.